JP4160505B2 - 自己免疫疾患の治療の構想における翻訳後型修飾を含むペプチドの使用 - Google Patents

自己免疫疾患の治療の構想における翻訳後型修飾を含むペプチドの使用 Download PDF

Info

Publication number
JP4160505B2
JP4160505B2 JP2003528859A JP2003528859A JP4160505B2 JP 4160505 B2 JP4160505 B2 JP 4160505B2 JP 2003528859 A JP2003528859 A JP 2003528859A JP 2003528859 A JP2003528859 A JP 2003528859A JP 4160505 B2 JP4160505 B2 JP 4160505B2
Authority
JP
Japan
Prior art keywords
lysine
seq
sequence
serine
acetylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003528859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005510469A (ja
JP2005510469A5 (cg-RX-API-DMAC10.html
Inventor
ミュレール，シルヴィアンヌ
モネオ，ファニー・シルビー・ミッシェル
ブリアン，ジャン−ポール
ギシャール，ジル
ギレ，ジャン−ジェラール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Original Assignee
Centre National de la Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique filed Critical Centre National de la Recherche Scientifique
Publication of JP2005510469A publication Critical patent/JP2005510469A/ja
Publication of JP2005510469A5 publication Critical patent/JP2005510469A5/ja
Application granted granted Critical
Publication of JP4160505B2 publication Critical patent/JP4160505B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
JP2003528859A 2001-09-18 2002-09-18 自己免疫疾患の治療の構想における翻訳後型修飾を含むペプチドの使用 Expired - Lifetime JP4160505B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0112041A FR2829768B1 (fr) 2001-09-18 2001-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
PCT/FR2002/003186 WO2003025014A2 (fr) 2001-09-18 2002-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes

Publications (3)

Publication Number Publication Date
JP2005510469A JP2005510469A (ja) 2005-04-21
JP2005510469A5 JP2005510469A5 (cg-RX-API-DMAC10.html) 2005-12-22
JP4160505B2 true JP4160505B2 (ja) 2008-10-01

Family

ID=8867384

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003528859A Expired - Lifetime JP4160505B2 (ja) 2001-09-18 2002-09-18 自己免疫疾患の治療の構想における翻訳後型修飾を含むペプチドの使用

Country Status (7)

Country Link
US (3) US7872098B1 (cg-RX-API-DMAC10.html)
EP (2) EP2338908A1 (cg-RX-API-DMAC10.html)
JP (1) JP4160505B2 (cg-RX-API-DMAC10.html)
AU (1) AU2002362383B2 (cg-RX-API-DMAC10.html)
CA (1) CA2460704A1 (cg-RX-API-DMAC10.html)
FR (1) FR2829768B1 (cg-RX-API-DMAC10.html)
WO (1) WO2003025014A2 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2459811C (en) * 2001-09-06 2012-03-13 Cnrs-Centre National De La Recherche Scientifique Modified peptides and their use for the treatment of autoimmune diseases
FR2931360B1 (fr) * 2008-05-20 2012-05-18 Centre Nat Rech Scient Nanoparticules contenant un peptide, vecteurs les contenant et utilisations pharmaceutiques desdits nanoparticules et vecteurs
ES2618402T3 (es) * 2011-12-13 2017-06-21 Centre National De La Recherche Scientifique Péptidos modificados y su uso para tratar enfermedades autoinmunitarias
US10213482B2 (en) 2014-12-12 2019-02-26 Immupharma France Sa Methods of treating chronic inflammatory diseases
WO2021198135A1 (en) * 2020-03-29 2021-10-07 Immupharma France Sa Method of treating viral infections
CN119241701B (zh) * 2024-09-27 2026-04-28 珠海丽禾医疗诊断产品有限公司 U1-70k结合蛋白、制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2459811C (en) * 2001-09-06 2012-03-13 Cnrs-Centre National De La Recherche Scientifique Modified peptides and their use for the treatment of autoimmune diseases

Also Published As

Publication number Publication date
WO2003025014A3 (fr) 2004-02-19
JP2005510469A (ja) 2005-04-21
EP2338908A1 (fr) 2011-06-29
US20140004136A1 (en) 2014-01-02
FR2829768B1 (fr) 2003-12-12
US7872098B1 (en) 2011-01-18
EP1427755A2 (fr) 2004-06-16
WO2003025014A2 (fr) 2003-03-27
CA2460704A1 (fr) 2003-03-27
AU2002362383B2 (en) 2008-10-09
US8475800B2 (en) 2013-07-02
FR2829768A1 (fr) 2003-03-21
US20120149652A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
JP5315372B2 (ja) Ｃｘｃｒ４拮抗薬およびその用途
Matsoukas et al. Design and synthesis of a novel potent myelin basic protein epitope 87− 99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators
US7579432B2 (en) Cyclic peptides as G-protein-coupled receptor antagonists
CA3049353C (en) Mycobacteria tuberculosis chaperonin 60.1 peptides and uses thereof
US8475800B2 (en) Phosphorylated derivatives of a U1-70K peptide and their use in the treatment of autoimmune pathologies
JP4212651B2 (ja) サソリ由来神経ペプチド
JPWO1998029446A1 (ja) サソリ由来神経ペプチド
US5856305A (en) Peptides endowed with antiinflammatory activity
AU744907B2 (en) Peptides comprising a T-cell epitope specific to collagen II
US5786334A (en) Hexapeptide having immunostimulatory activity
JP4781621B2 (ja) Ｃｘｃｒ４拮抗薬およびその用途
JP2002521387A (ja) 共重合体１および関連する共重合体ならびにペプチドによる自己免疫疾患の治療
JP3734855B2 (ja) ペプチド及びその用途
RU2144038C1 (ru) Пептиды для ингибирования высвобождения пепсина, фармацевтическая композиция
JP4171794B2 (ja) ペプチド及びその用途
KR101019246B1 (ko) 역순 광학 이성체 펩티드를 포함하는 약제학적 조성물
EP4661892A1 (en) Tnf-alpha binding agents and methods of using the same
JP3980016B2 (ja) ペプチドとその用途
JPH0680695A (ja) ペプチド
TW200526689A (en) Amniotic-derived peptide and uses thereof
EA019358B1 (ru) Аллель- и изотип-специфическая интервенция в ассоциированные с аутоиммунными заболеваниями молекулы класса ii мнс при помощи пептидов
AU3142102A (en) Peptides comprising a T-cell epitope specific to collagen II

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20080311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080609

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080701

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080717

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4160505

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110725

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110725

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120725

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120725

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130725

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term